1. Lorenzo Refolo & M-D Kerns
National Institute on Aging Small Business Awards to Advance Research on Alzheimer’s Disease and Alzheimer’s –Related Dementias
Lorenzo Refolo & M-D Kerns
National Institute on Aging

2. The NIA SBA Program aims to support the discovery, development and commercialization of new therapies, novel devices, analytical tools, health care programs and practices that will improve prevention and treatment, as well as caregiving for patients with AD/ADRD.

3. Broadly speaking the NIA SBA Program will support research that address the following topics:
Prevention
Diagnosis
Treatment
Care
Analytical Tools

4. Application Types Phase I- feasibility and proof-of-concept
Phase II-continue R&D initiated in Phase I
- funding is based on results achieved in Phase I + scientific and technical merit and commercial potential of the project proposed in Phase II
Fast Track- 1 application for Phase I and Phase II that is submitted and reviewed together
Phase IIB Competing Renewal- for projects that require additional funding beyond the original Phase II award. These applications require competitive peer review.
Direct to Phase II- for Phase II R&D for projects that have demonstrated the scientific and technical merit, feasibility and proof of concept

5. Currently Active SBIR & STTR Funding Opportunities
PA /Parent SBIR [R43/R44]
Application Types Allowed
-new Phase I, new Fast Track, Phase II renewal, Phase IIB-competing renewal
Application Due Dates
-Sept 5, Jan 5, April 5
3. Expiration Date
-April 6, 2017
4. Award Budget
-statutory guidelines -$150K (Phase 1), $1.0M (Phase II)
-for specific topics and with appropriate justification ->$225K (Phase I) , >$1.5M (Phase II)
***Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines

6. PAR-14-088 Direct Phase II SBIR [R44]
Application Types Allowed
- new Direct Phase II
2. Application Due Dates
- Sept 5, Jan 5, April 5
3. Expiration Date
- January 8, 2017
4. Award Budget
- statutory guidelines :$1.0M
- for specific topics and with appropriate justification $2.0M/ 3yrs

7. PA-16-303/ Parent STTR[R41/R42]
Application Types Allowed
- new Phase I, new Fast Track, Phase II renewal, Phase IIB-competing renewal
Application Due Dates
- Sept 5, Jan 5, April 5
3. Expiration Date
- April 6, 2017
4. Award Budget
- statutory guidelines -$150K (Phase 1), $1.0M (Phase II)
- for specific topics and with appropriate justification ->$225K (Phase I) , >$1.5M (Phase II)
***Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines

8. Coming Soon
Advancing Research on Alzheimer's Disease and Alzheimer's-related Dementias (ADRD) (R43/R44)
- $15M set aside for 2017
Advancing Research on Alzheimer's Disease and Alzheimer's-related Dementias (ADRD) (R41/R42)
- $5M set aside for 2017

9. NIA SBC Opportunities for AD Translational Research Funding
Discovery/Preclinical Development
STTR/SBIR
Drug Discovery for Nervous System Disorders
Alzheimer’s Drug Development Program
NIH
Target ID
Assay
Development
Screening
Hits to
Leads
Lead
Optimization
Candidate
Selection
IND-enabling
studies
IND
Phase I
Assay Development and Screening
Chemical Probe Development
Blueprint Neurotherapeutics Program
Clinical Development
AD Pilot Ph1/Ph2
AD Ph3
Phase I
Phase II
Phase III
SBIR

10. Other Funding Opportunities Open to SBCs
PAR : HTS to Discovery Chemical Probes (R01)
PAR : Discovery of in vivo Chemical Probes
PAR : Blueprint Neurotherapeutics Network :Small Molecule Drug Discovery for Disorders of the Nervous System (UH2/UH3)
PAR : Alzheimer’s Drug Development Program (U01)
PAR : Drug Discovery for Nervous System Disorders
PAR : Pilot Clinical Trials for the Spectrum of Alzheimer’s Disease and Age-related Cognitive Decline (R01)
PAR : Phase III Clinical Trials for the Spectrum of Alzheimer’s Disease and Age-related Cognitive Decline (R01)

11. Program Contacts
Dr. Lorenzo Refolo Dr. Michael-David A.R.R. Kerns